Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.12 - $6.32 $20,188 - $30,968
-4,900 Reduced 12.41%
34,600 $218,000
Q1 2024

May 15, 2024

BUY
$4.07 - $8.68 $117,623 - $250,852
28,900 Added 272.64%
39,500 $286,000
Q4 2023

Feb 14, 2024

BUY
$3.71 - $5.14 $39,326 - $54,484
10,600 New
10,600 $53,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.